HIKAL
|
|
BOM : 524735     NSE : HIKAL     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 07,2023 |
Price(EOD): βΉ 322.25
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 3,973.34 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
HIKAL | 3.8% | 7.4% | 2.7% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 5.9% | 17.9% |
DIVIS LABORATORIES | 0.5% | 4.8% | 0.3% |
CIPLA | -0.4% | 2.3% | -1.5% |
DR REDDYS LABORATORIES | 2.6% | -5.3% | 7% |
TORRENT PHARMACEUTICALS | 1.5% | 9.3% | 27.1% |
ABBOTT INDIA | 1.3% | -0.2% | 18.8% |
ZYDUS LIFESCIENCES | 0.3% | -1.9% | 41.3% |
ALKEM LABORATORIES | 0.8% | -5.8% | 9.5% |
FUNDAMENTAL ANALYSIS OF HIKAL
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF HIKAL
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
50.69
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 78.39 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] 3.51
P/B Calculated based on Book Value of Rs 1,133.47 Cr
[Latest Year - Mar2023 - Consolidated Results ] 1.96
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,023.03 Cr
[Latest Qtr - Mar2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
52% 28% 65% |
SHARE PRICE MOMENTUM OF HIKAL
HIKAL vs SENSEX
DEBT OF HIKAL
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.63 0.65 0.79 0.69 |
0.63 0.65 0.79 0.69 |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF HIKAL
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF HIKAL
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.94% 18.01% 35.74% 36.31% |
8.55% 44.3% 67.81% 73.83% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2023 | ||
Quarterly Result Analysis → |
HIKAL related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 3.3% | 7.1% | 18.8% |
S&P BSE 250 SMALLCAP | 3.2% | 6.7% | 20.4% |
S&P BSE HEALTHCARE | 3.2% | 5.1% | 10% |
S&P BSE MIDSMALLCAP | 2.9% | 6.7% | 19.4% |
S&P BSE 400 MIDSMALLCAP | 2.5% | 6% | 19.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | 3.3% | 7.1% | 17.3% |
NIFTY MID SMALL400 | 2.6% | 6.3% | 20% |
NIFTY500 MULTICAP 50:25:25 | 2% | 4.8% | 15.5% |
NIFTY 500 | 1.5% | 3.8% | 13.7% |
You may also like the below Video Courses
FAQ about HIKAL
Is HIKAL good for long term investment?
As on Jun 07,2023, the Fundamentals of HIKAL look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of HIKAL . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is HIKAL UnderValued or OverValued?
As on Jun 07,2023, HIKAL is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of HIKAL ?
As on Jun 07,2023, the Intrinsic Value of HIKAL is Rs. 211.51 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 211.51
Fair Value [Median EV / Sales Model] : Rs. 252.55
Fair Value [Median Price / Sales Model] : Rs. 195.60
Estimated Median Fair Value of HIKAL : Rs. 211.51
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is HIKAL trading at a Premium or Discount?
As on Jun 07,2023, HIKAL is trading at a Premium of 52% based on the estimates of Median Intrinsic Value!